Press - European Hematology Association

Press

For the latest news from EHA, please visit the section EHA Press Releases.

The media regulations and press registration information for the 18^th Congress of EHA Are available.

In order to register for the Press program, please send a mail, with a copy of your press credentials attached to communication@ehaweb.org. Please mention in the subject of your e-mail: Press registration EHA18. Your credentials will be checked and when approved, you will receive an link to the online press registration.

Press Briefing Prgram

Date/Time: Friday June 14, 2013 - 8:30 - 10:00 A.M.

Location: Hall C5 Stockholmmässan, Stockholm, Sweden

Moderator: Dr Anton Hagenbeek

Press Briefing Prgram

Date/Time: Friday June 14, 2013 - 8:30 - 10:00 A.M.
Location: Hall C5 Stockholmmässan, Stockholm, Sweden
Moderator: Dr Anton Hagenbeek

Time	Topic	Speaker
08:30	Start Press Briefing
08:30 – 08:35	Introduction	Dr Anton Hagenbeek, Moderator
08:35 – 08:40	“European Hematology Association”	Dr Ulrich Jäger, EHA President
08:40 – 08:45	Scientific Program EHA18 including the progress in basic science in the field of childhood leukemias	Dr Jorge Sierra, Chair SPC
08:45 – 08:50	Questions by media representatives
08:50 – 08:55	View on small molecules in lymphoma/leukemia	Dr Wyndham H. Wilson
08:55 – 09:00	Questions by media representatives
09:00 – 09:05	Age and Aging in blood disorders	Dr Pieter Sonneveld
09:05 – 09:10	Questions by media representatives
09:10 – 09:15	Efficacy, Safety and Quality of Life in MM-003, a phase3, multicenter, randomized, open label study of Pomalidomide (POM) + low-dose Dexamethasone (lodex) vs high-dose Dexamethasone (hidex) in relapsed/refractory multiple myeloma	Dr Jesus San Miguel
09:15 – 09:20	Questions by media representatives
09:20 – 09:25	Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma- an open label, dose escalation followed by open label-extension in a single-arm phase I/II study	Dr Henk Lokhorst
09:25 – 09:30	Questions by media representatives
09:30 – 09:35	Potential use of minihepcidins as therapeutics to prevent iron overload	Dr Elizabeta Nemeth
09:35 – 09:40	Questions by media representatives
09:40 – 09:45	JAK-STAT pathway in malignant and non-malignant cells contributes to myeloproliferative neoplasms pathogenesis and therapeutic response	Dr Ross L. Levine
09:45 – 09:50	Questions by media representatives
09:50 – 09:55	Obinutuzumab (GA101) or Rituximab (R) + Chlorambucil (CLB) versus CLB alone in patients with Chronic Lymphocytic Leukemia and pre-existing medical conditions (comorbidities): Final stage 1 results of the CLL11 phase 3 trial	Dr Valentin Goede
09:55 – 10:00	Questions by media representatives
10:00	Conclusion

Press contact:

EHA Executive Office
Communication & Press

Ineke van der Beek

Jon Tarifa